Cellectar Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
CLRB$1.28+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporation by Reference | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ExhibitNo. · Description · Filed withthisForm 10-Q · Form · Filing Date · ExhibitNo. | ||||||||||
| | | | | | | | | | | |
| 10.1 | | Form of Common Warrant | | | | S-1/A | | June 30, 2025 | | 4.2 |
| | | | | | | | | | | |
| 10.2 | | Form of Pre-Funded Warrant | | | | S-1/A | | June 30, 2025 | | 4.3 |
| | | | | | | | | | | |
| 10.3 | | Form of Representative Warrant | | | | S-1/A | | June 30, 2025 | | 4.4 |
| | | | | | | | | | | |
| 10.4 | | Form of Warrant Agency Agreement | | | | S-1/A | | June 30, 2025 | | 4.5 |
| | | | | | | | | | | |
| 10.5 | | Inducement Letter in consideration for Exercise of the Common Stock Purchase Warrants issued on October 25, 2022, July 21, 2024 and July 2, 2025 | | | | 8-K | | October 10, 2025 | | 10.1 |
| | | | | | | | | | | |
| 10.6 | | Form of Series I Common Stock Purchase Warrant | | | | 8-K | | October 10, 2025 | | 4.1 |
| | | | | | | | | | | |
| 10.7 | | Form of Series II Common Stock Purchase Warrant | | | | 8-K | | October 10, 2025 | | 4.2 |
| | | | | | | | | | | 3.1 |
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||||||
| 101 | Interactive Data Files | X | ||||||||
| 104 | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit). | | X | | | | | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CELLECTAR BIOSCIENCES, INC. | ||
| Date: November 13, 2025 | By: | /s/ James V. Caruso |
|---|---|---|
| James V. Caruso | ||
| President and Chief Executive Officer | ||
| | | (Principal Executive Officer) |
| | | |
| Date: November 13, 2025 | By: | /s/ Chad J. Kolean |
| | | Chad J. Kolean |
| | | Chief Financial Officer |
| | | (Principal Financial and Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.